Shares of Pfizer Inc. (PFE) slipped nearly 1.5% on Tuesday afternoon, even as the pharmaceutical giant posted a stronger-than ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its ...

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Stocks closed the week slightly higher after Monday’s sell-off prompted by concerns over China’s DeepSeekopen-source API. In fact, the tech-heavy NASDAQ index was on pace to be the best-performing ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.